|
|
|
Volumn 2, Issue 3, 2001, Pages 422-423
|
|
Overview: Recent success with the tyrosine kinase inhibitor STI-571 - Lessons for targeted therapy of cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMINOPYRIDINE DERIVATIVE;
BCR ABL PROTEIN;
IMATINIB;
MONOCLONAL ANTIBODY;
PLATELET DERIVED GROWTH FACTOR RECEPTOR;
PROTEIN TYROSINE KINASE;
PROTEIN TYROSINE KINASE INHIBITOR;
RETINOIC ACID;
RITUXIMAB;
TRASTUZUMAB;
ANTINEOPLASTIC AGENT;
ENZYME INHIBITOR;
PIPERAZINE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
BONE MARROW TRANSPLANTATION;
CANCER CHEMOTHERAPY;
CHROMOSOME MUTATION;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG SAFETY;
DRUG TARGETING;
ENZYME INHIBITION;
GENE EXPRESSION;
HUMAN;
ONCOGENE C KIT;
PHILADELPHIA 1 CHROMOSOME;
REVIEW;
SIDE EFFECT;
COMPARATIVE STUDY;
DRUG ANTAGONISM;
DRUG EFFECT;
FORECASTING;
GENE TARGETING;
GENETICS;
ONCOGENE;
PATHOLOGY;
PHASE 1 CLINICAL TRIAL;
REMISSION;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE I;
ENZYME INHIBITORS;
FORECASTING;
GENE TARGETING;
GENES, ABL;
HUMANS;
LEUKEMIA, MYELOID, CHRONIC;
PIPERAZINES;
PROTEIN-TYROSINE KINASES;
PYRIMIDINES;
REMISSION INDUCTION;
|
|
EID: 0035064488
PISSN: 09678298
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (6)
|
|
References (0)
|
